The best way to be considered for current or future trials is to join the 'Permission to Contact' scheme for the Neuroprogressive & Dementia Network. This will allow the research team to access your medical records and check whether you are eligible for studies. To find out more details please visit https://www.nhsresearchscotland.org.uk/research-areas/dementia-and-neurodegenerative-disease.
To sign up for the 'Permission to Contact' scheme, please complete the online form https://www.nhsresearchscotland.org.uk/research-areas/dementia-and-neurodegenerative-disease/patient-signup-form. Alternatively you can email tay.ndntayside@nhs.scot or call 01382 423086 to have a paper form sent out.
Current available trials:
- RAPSODI GD
Remote assessment of Parkinsonism supporting ongoing development of interventions in Gaucher disease
Open to new recruits: Yes
Study Drug: No
Inclusion criteria: Anyone with a diagnosis of Parkinson’s Disease
Participating Scottish sites: Dundee
Website: https://www.parkinsons.org.uk/research/pd-frontline-identifying-genes-people-parkinsons
- PFP: Parkinson's and Movement Disorders Families Project
Open to New recruits: Yes
Study Drug: No
Inclusion Criteria: Anyone with a PD diagnosis AND any of the following:
- patient has a genetic mutation for PD
- family member (1st/2nd/3rd) with PD or MD (including tremor)
- symptom onset under 45 years of age
EJS-ACT-PD Study - See Parkinson's UK main page for registration link:
Objective: Accelerate clinical trials in Parkinson’s Disease by evaluating multiple treatments simultaneously
Design: Multi-Arm, Multi-Stage Trial
Focus: Regularly analysing several treatments to assess their effectiveness. Effective treatments will continue, while ineffective ones will be replaced with new options, ensuring no delays in the trial process.
Goal: To speed up the development of effective treatments for Parkinson’s Disease through a flexible and adaptive trial design
Open to new recruits: yes
LITE The MJFF LRRK2 Investigative Therapeutics Exchange (LITE) Study - is now open
Objective: To address critical gaps in our knowledge about Parkinson’s Disease (PD) by exploring genetic and biological markers to predict responses to new treatments
Focus: Investigate whether biological markers differ between people with PD and those without
•Examine how these markers could predict responses to treatments aimed at slowing or stopping disease progression
•Study why some people with a genetic risk for PD develop the disease while others with the same risk do not
- Collaborate with the Global Parkinson’s Genetics Program (GP2) to study the genetics of PD, involving both people with and without the disease
Goal: To improve our understanding of Parkinson’s Disease, develop new technologies and approaches for measuring the disease, and identify potential biomarkers for better diagnosis and treatment
More information to come...
Neulark - Study to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease (NEULARK)
Website: Neulark – A Clinical Trial for People with Parkinson's Disease Patients. The study will be added to the PUK website shortly.
- Objective: NEULARK is a Phase 2 clinical trial designed to evaluate the safety and effectiveness of an investigational drug, NEU-411, for treating LRRK2-driven Parkinson’s disease.
- Goal: This clinical trial is designed to investigate whether NEU-411 can potentially slow disease progression.
- Open to recruits – yes NHS Tayside
- Study Drug – yes oral tablet NEU-411/placebo
- Inclusion criteria:
- Aged 40-80 years old
- Diagnosed with earlystage Parkinson’s Disease
- Not currently on dopamine replacement therapies such as levodopa.
Paraiso – STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY-STAGE PARKINSON’S DISEASE
- No website.
- Objective: evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in participants with early-stage Parkinson’s disease (PD) on stable symptomatic monotherapy with levodopa.
- Goal: To test if the study drug can modify the course of the disease
- Open to recruits: yes, NHS Tayside
- Inclusion criteria:
- A diagnosis of PD for at least 3 months to a maximum of 3 years at screening
- ′Monotherapy treatment′ has been treated with the same unique treatment (levodopa only) for at least 3 months prior to baseline
- Age 50-80
-For further information of other research studies: https://bepartofresearch.nihr.ac.uk/